Skip to Main Content

A promising but controversial new approach to treating blood cancer could be in trouble in the earliest innings of human testing after Celgene pulled the plug on a trailblazing clinical trial.

On Monday, Celgene (CELG) terminated a Phase 1 study of CC-90002, which targets a protein that helps cancer cells stay out of the immune system’s crosshairs. In an update to, Celgene said it canceled the CC-90002 study because early results “did not offer a sufficiently encouraging profile” to move forward.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.